Acrux Ltd (Acrux) is focused on the development and commercialization of generic topical prescription products. The company operates in the pharmaceutical industry, specifically focusing on topical and transdermal drug delivery systems. The company has launched several products in the US market, including Dapsone 7.5% Gel for acne vulgaris, Nitroglycerin Ointment 0.4% for anal fissure pain, and Prilocaine 2.5% and Lidocaine 2.5% Cream as a topical anesthetic. It also markets Estradiol Spray for menopause symptoms and has a generic version of Jublia (efinaconazole) 10% Topical Solution for toenail fungal infections.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Acrux specializes in the development of topically applied pharmaceutical products, including gels, creams, ointments, and patches. The company holds a growing portfolio of FDA-approved Abbreviated New Drug Applications (ANDAs) and is expanding its pipeline with new products under development. Acrux leverages its internal expertise to create generic drugs targeting significant segments of the US topical market. The development process for these generics is faster and more cost-effective compared to new drug development. The company is also involved in the development of specialty topical drugs, including both branded and generic products, and can develop multiple dosage forms such as ointments, creams, gels, solutions, sprays, suspensions, and drops. Acrux’s proprietary know-how involves the use of FDA-approved penetration enhancers, facilitating effective drug delivery for conditions such as hormonal deficiencies, CNS disorders, contraception, pain, and dermatological issues. As of June 2025, the company has marketed five FDA-registered products in the US. In FY2025, the company invested AUD2.3 million in its R&D activities, which declined by 4.5% YoY and as a percentage of its revenue stood at 50.9%.